412 related articles for article (PubMed ID: 23840064)
1. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Pfeifer M; Grau M; Lenze D; Wenzel SS; Wolf A; Wollert-Wulf B; Dietze K; Nogai H; Storek B; Madle H; Dörken B; Janz M; Dirnhofer S; Lenz P; Hummel M; Tzankov A; Lenz G
Proc Natl Acad Sci U S A; 2013 Jul; 110(30):12420-5. PubMed ID: 23840064
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
[TBL] [Abstract][Full Text] [Related]
4. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma.
Pfeifer M; Lenz G
Cell Cycle; 2013 Nov; 12(21):3347-8. PubMed ID: 24091535
[No Abstract] [Full Text] [Related]
5. Targeting PIN-1 Attenuates GCB DLBCL Cell Proliferation Through Inhibition of PI3K/AKT Signaling.
Yang H; Zhang P; Li J; Gao Y; Zhao L; Li J; Guo M; Zhang J; Li H; Wang F; Yuan Y
Onco Targets Ther; 2020; 13():8593-8600. PubMed ID: 32904547
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL.
Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J
Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817
[TBL] [Abstract][Full Text] [Related]
7. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma.
Havranek O; Xu J; Köhrer S; Wang Z; Becker L; Comer JM; Henderson J; Ma W; Man Chun Ma J; Westin JR; Ghosh D; Shinners N; Sun L; Yi AF; Karri AR; Burger JA; Zal T; Davis RE
Blood; 2017 Aug; 130(8):995-1006. PubMed ID: 28646116
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT inhibition reverses R-CHOP resistance by destabilizing SOX2 in diffuse large B cell lymphoma.
Chen J; Ge X; Zhang W; Ding P; Du Y; Wang Q; Li L; Fang L; Sun Y; Zhang P; Zhou Y; Zhang L; Lv X; Li L; Zhang X; Zhang Q; Xue K; Gu H; Lei Q; Wong J; Hu W
Theranostics; 2020; 10(7):3151-3163. PubMed ID: 32194860
[TBL] [Abstract][Full Text] [Related]
9. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma.
Xu W; Berning P; Erdmann T; Grau M; Bettazová N; Zapukhlyak M; Frontzek F; Kosnopfel C; Lenz P; Grondine M; Willis B; Lynch JT; Klener P; Hailfinger S; Barry ST; Lenz G
Leukemia; 2023 Jan; 37(1):178-189. PubMed ID: 36352190
[TBL] [Abstract][Full Text] [Related]
11. PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells.
Zhu F; Guo H; Bates PD; Zhang S; Zhang H; Nomie KJ; Li Y; Lu L; Seibold KR; Wang F; Rumball I; Cameron H; Hoang NM; Yang DT; Xu W; Zhang L; Wang M; Capitini CM; Rui L
Leukemia; 2019 Dec; 33(12):2898-2911. PubMed ID: 31123343
[TBL] [Abstract][Full Text] [Related]
12. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Lenz G; Wright GW; Emre NC; Kohlhammer H; Dave SS; Davis RE; Carty S; Lam LT; Shaffer AL; Xiao W; Powell J; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Campo E; Jaffe ES; Delabie J; Smeland EB; Rimsza LM; Fisher RI; Weisenburger DD; Chan WC; Staudt LM
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13520-5. PubMed ID: 18765795
[TBL] [Abstract][Full Text] [Related]
13. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated expressions of PTEN, NF-κB, WWP2, p53 and c-Myc in different subtypes of B cell lymphoma and reactive follicular hyperplasia.
Fu H; Jin C; Zhu Q; Liu T; Ke B; Li A; Zhang T
Am J Transl Res; 2019; 11(2):1092-1101. PubMed ID: 30899409
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
[TBL] [Abstract][Full Text] [Related]
16. TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods.
Gao HX; Li SJ; Niu J; Ma ZP; Nuerlan A; Xue J; Wang MB; Cui WL; Abulajiang G; Sang W; Zhang W; Li XX
Pathol Res Pract; 2020 Feb; 216(2):152799. PubMed ID: 31932115
[TBL] [Abstract][Full Text] [Related]
17. PTEN Loss and Cyclin A2 Upregulation Define a PI3K/AKT Pathway Activation in Helicobacter pylori-induced MALT and DLBCL Gastric Lymphoma With Features of MALT.
Ben Younes K; Doghri R; Mrad K; Bedhiafi W; Benammar-Elgaaied A; Sola B; Ben Aissa-Fennira F
Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):56-61. PubMed ID: 32134755
[TBL] [Abstract][Full Text] [Related]
18. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
19. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas.
Lu X; Nechushtan H; Ding F; Rosado MF; Singal R; Alizadeh AA; Lossos IS
Blood; 2005 Apr; 105(7):2924-32. PubMed ID: 15591113
[TBL] [Abstract][Full Text] [Related]
20. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas.
van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L
PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]